Home › Head and Neck Squamous Cell Carcinoma › Illinois › Chicago
Head and Neck Squamous Cell Carcinoma clinical trials in Chicago, IL
29 studies for Head and Neck Squamous Cell Carcinoma are looking for participants at sites in and around Chicago (within about 30 miles). Open a study to see who can join and how to contact the study team.
Recruiting for a study here? Feature it at the top of this page — $99 for 30 days →
Testing What Happens When an Immunotherapy Drug (Pembrolizumab) is Given by Itself Compared to the Usual Treatment of Chemotherapy With Radiation After Surgery for Recurrent Head and Neck Squamous Cell Carcinoma
RecruitingPhase 2
- Northwestern University, Chicago
- John H Stroger Jr Hospital of Cook County, Chicago
- University of Illinois, Chicago
BiCaZO: A Study Combining Two Immunotherapies (Cabozantinib and Nivolumab) to Treat Patients With Advanced Melanoma or Squamous Cell Head and Neck Cancer, an immunoMATCH Pilot Study
RecruitingPhase 2
- Northwestern University, Chicago
- University of Illinois, Chicago
Testing the Addition of Anti-Cancer Drug, Cetuximab, to Standard of Care Treatment (Pembrolizumab) for Returning or Spreading Head and Neck Cancer After Previous Treatment
RecruitingPhase 3
- University of Chicago Comprehensive Cancer Center, Chicago
- Advocate Illinois Masonic Medical Center, Chicago
Study of INBRX-106 and INBRX-106 in Combination With Pembrolizumab (Keytruda®) in Subjects With Locally Advanced or Metastatic Solid Tumors (Hexavalent OX40 Agonist)
RecruitingPhase 1/2
- University of Illinois Cancer Center, Chicago
A Study of LY4052031 in Participants With Advanced or Metastatic Urothelial Cancer or Other Solid Tumors
RecruitingPhase 1
- University of Chicago Hospital, Chicago
High-dose Prophylactic Gabapentin (HOPE) vs. Placebo to Prevent Opioid Use for Oral Mucositis Pain During Concurrent Chemoradiation for Head and Neck Cancer
RecruitingPhase 3
- Advocate Illinois Masonic Medical Center, Chicago
A Study of Amivantamab Alone or in Addition to Other Treatment Agents in Participants With Head and Neck Cancer
RecruitingPhase 1/2
- The University of Chicago Medical Center (UCMC), Chicago
A Study of Amivantamab in Addition to Standard of Care Agents (SOC) Compared With SOC Alone in Participants With Recurrent/Metastatic Head and Neck Cancer
RecruitingPhase 3
- Rush University Medical Center Rush University Cancer Center Chicago, Chicago
- The University of Chicago Medical Center (UCMC), Chicago
FORTIFI-HN01: A Study of Ficerafusp Alfa (BCA101) or Placebo in Combination With Pembrolizumab in First-Line PD-L1-pos, R or M HNSCC
RecruitingPhase 2/3
- Captain James A Lovell Federal Health Care Center-VA North Chicago (Site # 133), Chicago
Ordastobart (INBRX-106) Add-on to Pembrolizumab in 1L HPV+ PD-L1+ R/M OPSCC (HexAgon-HN)
RecruitingPhase 2/3
- University of Illinois Cancer Center, Chicago
A Study to Investigate ALE.P02 as a Monotherapy or in Combination With Pembrolizumab in Adult Patients With Selected CLDN1+ Solid Tumors
RecruitingPhase 1/2
- The University of Chicago Medical Center - Oncology, Chicago
SMP-3124LP in Adults With Advanced Solid Tumors
RecruitingPhase 1/2
- Northwestern Medicine Cancer Center, Chicago
- The University of Chicago, Chicago
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400
RecruitingPhase 1
- Northwestern Medicine - Northwestern Memorial Hospital /ID# 257378, Chicago
- University of Chicago Medical Center /ID# 258197, Chicago
A Study to Evaluate CRB-701 Compared to Investigator's Choice Therapy in Previously Treated Oropharyngeal Squamous Cell Carcinoma
RecruitingPhase 3
- University of Chicago, Chicago
Study of Zanzalintinib in Combination With Immuno-Oncology or Other Agents in Participants With Solid Tumors
RecruitingPhase 1
- Exelixis Clinical Site #26, Chicago
Evaluate BL-B01D1 in Patients With Metastatic or Unresectable Non-Small Cell Lung Cancer (NSCLC) and Other Solid Tumors
RecruitingPhase 1
- Northwestern University Feinberg School of Medicine, Chicago
Radiation Therapy With or Without Cisplatin in Treating Patients With Stage III-IVA Squamous Cell Carcinoma of the Head and Neck Who Have Undergone Surgery
RecruitingPhase 2
- John H Stroger Jr Hospital of Cook County, Chicago
- University of Chicago Comprehensive Cancer Center, Chicago
- Advocate Illinois Masonic Medical Center, Chicago
A Longitudinal Multi-Omic Biomarker Profiling Study of Patients With Head & Neck Squamous Cell Carcinoma (HNSCC)
RecruitingObservational study
- Northwestern University Feinberg School of Medicine, Chicago
A Study to Assess the Adverse Events, Change in Disease Activity, and How Oral ABBV-711 Tablets Move Through the Body as a Monotherapy and in Combination With Intravenously Infused Budigalimab (ABBV-181), in Adults With Advanced Squamous Tumors
RecruitingPhase 1
- University of Chicago Medical Center /ID# 276638, Chicago
Comparing Sentinel Lymph Node (SLN) Biopsy With Standard Neck Dissection for Patients With Early-Stage Oral Cavity Cancer
RecruitingPhase 2/3
- Northwestern University, Chicago
- Rush MD Anderson Cancer Center, Chicago
Testing the Addition of the Drug BMX-001, a Radioprotector, or a Placebo to the Usual Chemoradiation Therapy for Patients With Head and Neck Cancer
RecruitingPhase 2
- Northwestern University, Chicago
A Study of Sigvotatug Vedotin in Advanced Solid Tumors
RecruitingPhase 1
- UChicago Medicine - River East, Chicago
- The University Of Chicago, Chicago
- University of Chicago Medical Center, Chicago
Study to Assess Adverse Events and Pharmacokinetics in Adult Participants With Non-Small Cell Lung Cancer, Head and Neck Squamous Cell Carcinoma and Other Solid Tumors, Receiving Intravenous Infusion of Azirkitug Alone or in Combination(s) With Budigalimab, Bevacizumab, or Telisotuzumab Adizutecan
RecruitingPhase 1
- University of Illinois Hospital and Health Sciences System /ID# 251750, Chicago
- University of Chicago Medical Center /ID# 276271, Chicago
A Study of Pembrolizumab in Combination With Chemotherapy for Head and Neck Cancer
RecruitingPhase 2
- University of Chicago Comprehensive Cancer Center, Chicago
A Study Evaluating the Safety and Efficacy of PRV111, PRV211, and PRV131 in Subjects With Oral and Lung Cancers
RecruitingPhase 2/3
- The University of Chicago, Chicago
A Study of Ficlatuzumab in Combination With Cetuximab in Participants With Recurrent or Metastatic (R/M) HPV Negative Head and Neck Squamous Cell Carcinoma
RecruitingPhase 3
- University of Illinois Cancer Center, Chicago
Dosing Study of Radiation Combined With Tislelizumab and Pamiparib in Patients With Previously Treated Head and Neck Cancer
RecruitingPhase 1
- The University of Chicago, Chicago
A Study of CLSP-1025 in Adult Patients With Solid Tumors That Harbor the p53 R175H Mutation
RecruitingPhase 1
- The University of Chicago Comprehensive Cancer Center, Chicago
A Study of NX-1607 in Adults With Advanced Malignancies
RecruitingPhase 1
- University of Chicago, Chicago
Head and Neck Squamous Cell Carcinoma trials in other cities
- Houston, TX49 studies
- Nashville, TN43 studies
- Los Angeles, CA43 studies
- Boston, MA42 studies
- New York City, NY42 studies
- St. Louis, MO32 studies
- Arlington, VA29 studies
- Philadelphia, PA25 studies
- Pittsburgh, PA23 studies
- Atlanta, GA22 studies
- New Haven, CT22 studies
- Dallas, TX22 studies
Other studies in Chicago
- Breast Cancer59 studies
- Non-Small Cell Lung Cancer59 studies
- Cancer (all types)51 studies
- Prostate Cancer45 studies
- Lung Cancer43 studies
- Metastatic Cancer42 studies
- Obesity40 studies
- Ovarian Cancer36 studies
- Colorectal Cancer32 studies
- Stroke31 studies
- Overweight29 studies
- Heart Failure28 studies
From ClinicalTrials.gov, data retrieved Nov 15, 2026. Each study sets its own eligibility; the study team decides who can join.